DekaBank Deutsche Girozentrale Sells 14,951 Shares of Regeneron Pharmaceuticals Inc (REGN)

DekaBank Deutsche Girozentrale lessened its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 24.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 47,178 shares of the biopharmaceutical company’s stock after selling 14,951 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Regeneron Pharmaceuticals were worth $19,396,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in REGN. FMR LLC raised its position in Regeneron Pharmaceuticals by 17.0% in the 3rd quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock valued at $2,026,867,000 after buying an additional 728,104 shares during the last quarter. Alliancebernstein L.P. raised its position in Regeneron Pharmaceuticals by 35.8% in the 3rd quarter. Alliancebernstein L.P. now owns 1,023,594 shares of the biopharmaceutical company’s stock valued at $413,573,000 after buying an additional 269,696 shares during the last quarter. Ffcm LLC grew its stake in Regeneron Pharmaceuticals by 27,119.4% in the third quarter. Ffcm LLC now owns 256,407 shares of the biopharmaceutical company’s stock valued at $11,599,000 after purchasing an additional 255,465 shares in the last quarter. Janus Henderson Group PLC grew its stake in Regeneron Pharmaceuticals by 12.7% in the second quarter. Janus Henderson Group PLC now owns 1,802,740 shares of the biopharmaceutical company’s stock valued at $621,927,000 after purchasing an additional 203,306 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. grew its stake in Regeneron Pharmaceuticals by 83.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 346,383 shares of the biopharmaceutical company’s stock valued at $139,953,000 after purchasing an additional 157,800 shares in the last quarter. 66.83% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ REGN opened at $340.86 on Friday. The company has a quick ratio of 3.30, a current ratio of 4.04 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals Inc has a 12 month low of $281.89 and a 12 month high of $416.49. The company has a market cap of $37.13 billion, a PE ratio of 25.42, a price-to-earnings-growth ratio of 1.19 and a beta of 1.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The company had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period in the previous year, the company posted $3.99 EPS. The firm’s revenue for the quarter was up 10.8% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals Inc will post 19.48 EPS for the current year.

In other news, major shareholder Sanofi sold 104,552 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $388.65, for a total value of $777,300.00. Following the transaction, the director now owns 13,000 shares of the company’s stock, valued at $5,052,450. The disclosure for this sale can be found here. Insiders have sold a total of 108,552 shares of company stock valued at $44,081,027 over the last quarter. 12.42% of the stock is currently owned by corporate insiders.

A number of research analysts have weighed in on REGN shares. Cantor Fitzgerald raised their price target on Regeneron Pharmaceuticals to $441.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. SunTrust Banks restated a “hold” rating and issued a $400.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, August 3rd. ValuEngine upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 6th. JPMorgan Chase & Co. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 2nd. Finally, Leerink Swann raised their price target on Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the company an “outperform” rating in a research note on Monday, October 1st. Two analysts have rated the stock with a sell rating, seventeen have given a hold rating and five have given a buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $402.37.

WARNING: “DekaBank Deutsche Girozentrale Sells 14,951 Shares of Regeneron Pharmaceuticals Inc (REGN)” was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.wkrb13.com/2018/11/25/dekabank-deutsche-girozentrale-sells-14951-shares-of-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Earnings Per Share (EPS) Explained

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply